Straits Times Index
3,299.10 +6.41 (+0.19%) Nikkei
38,299.71 +25.66 (+0.07%) Hang Seng
18,150.33 +387.30 (+2.18%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,400.65 -2,585.97 (-4.31%) CMC Crypto 200
1,259.45 -79.62 (-5.95%)
CRISPR Therapeutics AG (CRSP)
After hours:
- Zacks
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
- Zacks
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.91, moving +0.34% from the previous trading session.
- Reuters
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA.
